Raymond James Financial
TRIB

Raymond James Financial’s Trinity Biotech TRIB Stock Holding History

Raymond James Financial’s Portfolio TRIB Stock Details TRIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11K Hold
677
– – ﹤0.01% 5247
2025
Q4 		$16.1K Hold
677
– – ﹤0.01% 5106
2025
Q3 		$21.1K Sell
677
-168
-20% -$5.3K ﹤0.01% 4898
2025
Q2 		$16.5K Hold
845
– – ﹤0.01% 5684
2025
Q1 		$14.5K Sell
845
-33
-4% -$781 ﹤0.01% 4749
2024
Q4 		$23.2K Buy
+878
New +$35.2K ﹤0.01% 4711

Other funds holding TRIB

HAIM
Hunter Associates Investment Management Pittsburgh, Pennsylvania $868M AUM 32.25% 1-Year Est. Return
YAG
Yorkville Advisors Global Mountainside, New Jersey $86.2M AUM 41.28% 1-Year Est. Return
WN
Williams & Novak Westlake Village, California $151M AUM 27.43% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
MAWA
Moss Adams Wealth Advisors Seattle, Washington $1.6B AUM 28.24% 1-Year Est. Return
IWA
Inspirion Wealth Advisors Libertyville, Illinois $874M AUM 16.23% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
BCM
Becker Capital Management Portland, Oregon $3.72B AUM 31.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Raymond James Financial's TRIB Position: Q1 2026 in Review

Raymond James Financial held its Trinity Biotech (TRIB) position steady in Q1 2026 at 677 shares worth $11K. The position accounts for ﹤0.01% of the portfolio, ranked #5247.

Raymond James Financial first reported a position in TRIB in Q4 2024 and has held it in 6 quarters since. The position peaked at $23.2K in Q4 2024. 21 funds tracked by Wall St. Rank hold TRIB as of Q1 2026.

  • Raymond James Financial held 677 shares of Trinity Biotech worth $11K as of Q1 2026.
  • Raymond James Financial left its Trinity Biotech share count unchanged in Q1 2026.
  • Trinity Biotech made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #5247 holding.
  • Raymond James Financial first reported a position in Trinity Biotech in Q4 2024 and has held it in 6 quarters since.
  • Raymond James Financial's Trinity Biotech position peaked at $23.2K in Q4 2024.
  • 21 funds tracked by Wall St. Rank held Trinity Biotech as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.